|
HS Code |
848790 |
| Chemical Name | Trans-4-(4-Methoxyphenyl)Pyrrolidine-3-Carboxylic Acid-Hcl |
As an accredited Trans-4-(4-Methoxyphenyl)Pyrrolidine-3-Carboxylic Acid-Hcl factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of Trans - 4 - (4 - Methoxyphenyl)Pyrrolidine - 3 - Carboxylic Acid - Hcl in sealed chemical - grade bags. |
| Shipping | Trans - 4 - (4 - Methoxyphenyl)Pyrrolidine - 3 - Carboxylic Acid - HCl will be shipped in a well - sealed, corrosion - resistant container. Packaging adheres to chemical shipping safety standards to prevent leakage during transit. |
| Storage | Trans - 4 - (4 - Methoxyphenyl)pyrrolidine - 3 - carboxylic acid - HCl should be stored in a cool, dry place, away from direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and exposure to air, which could potentially lead to degradation. Store it at a controlled temperature, typically around room temperature (15 - 25°C), to maintain its chemical stability. |
In the pursuit of selective norepinephrine reuptake inhibitors with attenuated muscarinic antagonism, trans-4-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride is introduced as the chiral linchpin in a multi-kilogram manufacturing route that bypasses classical resolution. The hydrochloride salt is first neutralised with aqueous sodium hydroxide (2.0 M) in ethyl acetate at 15–20°C; the organic layer is azeotropically dried to <100 ppm water (Karl Fischer, USP <921>) before charging into the amidation. Coupling with 2-(2-ethoxyphenoxy)ethylamine (1.02 molar equiv.) proceeds via 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.20 equiv.) and 1-hydroxybenzotriazole hydrate (0.10 equiv.) in N,N-dimethylformamide at −2 to 3°C for 12 h. After aqueous workup with 5% sodium bicarbonate and brine, the N-Boc protected amide is crystallised from cyclohexane/methyl tert-butyl ether (3:1 v/v) to afford a white solid with 99.3% HPLC purity (Waters Symmetry C18, 150×4.6 mm, acetonitrile/0.1% phosphoric acid gradient, UV 215 nm) and 99.8% ee (Chiralpak AD-H, 250×4.6 mm, n-hexane/ethanol/diethylamine 88/12/0.1, retention time 7.2 min). The penultimate intermediate is telescoped into a two-step deprotection-reductive methylation: first, trifluoroacetic acid (8.0 equiv.) in dichloromethane at 20°C for 3 h cleaves the Boc group; after solvent exchange to methanol, formaldehyde (37 wt% in water, 3.5 equiv.) and sodium cyanoborohydride (2.0 equiv.) are added at pH 5.0–5.5 (adjusted with acetic acid), maintaining 10–15°C. The resulting tertiary amine API—a dual norepinephrine-dopamine reuptake inhibitor—is isolated as the fumarate salt, displaying a Ki of 8.7 nM at hNET and 42 nM at hDAT in competition binding assays. Batch records from 50-L glass-lined reactors indicate that the hydrogen chloride content of the starting material must be strictly controlled (18.5–19.2% titration) because deviations exceeding 0.5% shift the amidation pH window and drop the diastereomeric excess below 98.5%. The product is shipped under nitrogen in double polyamide-aluminium foil bags with a maximum storage recommendation of 24 months at 2–8°C, supported by long-term stability data per ICH Q1A(R2) showing 0.15% total degradants at 36 months.A structurally diverse set of trans-4-aryl pyrrolidine-3-carboxamide ligands was advanced to preclinical toxicology for the treatment of neuropathic pain, exploiting this pyrrolidine acid as the common advanced intermediate. Following liberation of the free amine with potassium carbonate (2.5 equiv.) in isopropyl acetate, the pyrrolidine ester—prepared by treating the acid with thionyl chloride (1.10 equiv.) in methanol at −8°C and subsequent heating to reflux for 5 h—is subjected to lithium aluminium hydride reduction (1.50 equiv. in tetrahydrofuran, 0°C to 20°C over 2 h) to furnish the primary alcohol. This alcohol is converted to the corresponding mesylate (> 99% conversion by TLC) and displaced with selected substituted phenols under Mitsunobu conditions (diisopropyl azodicarboxylate 1.30 equiv., triphenylphosphine 1.30 equiv.) in toluene at 25°C, providing ether-linked candidates that maintain the trans geometry unambiguously (3JHH = 7.8–8.2 Hz in 400 MHz 1H NMR). The free base of the final ether is treated with hydrochloric acid in dioxane (4.0 M, 1.05 equiv.) to deliver the hydrochloride salt directly amenable to salt-form screening. A μ-opioid receptor agonist emerging from this series showed an EC50 of 3.4 nM in [35S]GTPγS functional assays and exceeded 95% oral bioavailability in male Sprague-Dawley rats when administered at 5 mg/kg. Critical process controls in the larger-scale (20-kg) campaigns included the residual aluminium content of the reduced alcohol intermediate, which had to be brought below 10 ppm (ICP-MS, USP <233>) by acidic Celite filtration to avoid emulsion formation in the Mitsunobu workup. The enantiospecific synthesis demands that any batch of the pyrrolidine acid hydrochloride containing more than 0.15% of the cis isomer be rejected, an attribute verified by an orthogonal capillary electrophoresis method (BGE: 50 mM sodium phosphate, pH 2.5, with 2% sulfated-β-cyclodextrin).Why Does the Purity Profile of the In-Situ Generated Acid Chloride Impact Asymmetric Alkylation Yields?When the pyrrolidine carboxylic acid is repurposed as a chiral controller in glycine Schiff base alkylations, the mode of activation directly dictates the diastereomeric ratio. Prior to use, the hydrochloride salt is suspended in dichloromethane and treated with triethylamine (2.20 equiv.) at 0–5°C; the liberated free acid is then added dropwise to a pre-mixed solution of oxalyl chloride (1.08 equiv.) and catalytic dimethylformamide (0.5 mol%) in the same solvent. If the resulting acid chloride solution is not degassed under vacuum (50 mbar for 15 min at 10°C) to expel residual HCl, the subsequent coupling with 2-aminobenzophenone-derived imine proceeds with 6–8% lower selectivity. The optimized protocol loads this acid chloride at −78°C into a lithium enolate formed from tert-butyl glycinate Schiff base and lithium bis(trimethylsilyl)amide (1.10 equiv. in THF). After 45 min at −78°C and quenching with glacial acetic acid (2.00 equiv.), the resultant protected β-aryl pyrrolidine amino acid—a core of constrained peptidomimetics—is obtained in 91% isolated yield and 99.2% de. The diastereomeric excess is sensitive to the alkali metal counterion: lithium base yields a dr of 99:1, whereas sodium hexamethyldisilazide drops the dr to 87:13 under identical conditions. Scale-up in 30-L jacketed reactors equipped with a −85°C circulating bath revealed that the stirring rate during the acid chloride addition must be kept at 350–400 rpm (anchor impeller) to prevent hotspots that locally raise the temperature above −65°C and form the opposite diastereomer. The final deprotected tert-butyl ester hydrochloride is routinely certified against ISO 9001:2015 for customers employing it as a non-coded amino acid in solid-phase peptide synthesis (SPPS) on 2-chlorotrityl chloride resin (loading capacity 1.0–1.2 mmol/g).Precursor for [11C]Methoxy-Labeled Neuroinflammation Imaging AgentsThe free base of this pyrrolidine derivative, freed immediately before use with sodium bicarbonate, serves as a high-affinity precursor for O-[11C]methylation in the preparation of translocator protein (TSPO) radioligands. Within a lead-shielded hot cell, the precursor (0.5 mg, 2.2 µmol) is dissolved in anhydrous N,N-dimethylformamide (300 µL) containing cesium carbonate (2.5 mg, 7.7 µmol). Cyclotron-produced [11C]methyl iodide (typical activity 55–74 GBq at end of bombardment) is bubbled into the solution at 25°C for 2 min. The reaction vial is sealed and heated at 80°C for 5 min, after which the crude mixture is diluted with 1.5 mL of water and injected onto a semi-preparative HPLC system (YMC-Pack ODS-A, 250×10 mm, 5 µm; mobile phase acetonitrile/0.1% phosphoric acid 45:55 v/v, flow rate 4.0 mL/min). The radiolabeled product elutes at 9.2–9.6 min and is collected into a flask containing 50 mL of water and 0.5 mL of 7.5% sodium bicarbonate, then trapped on a C18 Plus solid-phase extraction cartridge, washed with sterile water (10 mL), and eluted with absolute ethanol (1.5 mL). The final formulation, diluted with 10 mL of 0.9% sodium chloride for injection, passes release tests per USP <823>: radiochemical purity ≥99.0% (HPLC, UV 254 nm co-injection with the non-radioactive reference), molar activity 180–260 GBq/µmol, residual DMF ≤880 ppm, and ethanol content 9.8–10.2% v/v. Visual inspection under 20,000 lux confirms the absence of particulates. The entire synthesis, from end of bombardment to final sterile filtration through a 0.22 µm membrane, is completed within 33–37 min, compliant with the 60-min valid shelf life determined by radiolysis kinetics. Batch failure most commonly arises when the precursor free base has been stored in solution for more than 20 min prior to labeling, during which oxidative discoloration generates by-products that co-elute with the radiopeak; hence, the precursor is supplied in single-use, argon-flushed amber vials containing 5.0 mg of hydrochloride salt, which must be reconstituted immediately before radiosynthesis.Table 1 — Labeling Performance as a Function of Precursor Purity
When the Pyrrolidine-3-Carboxylic Acid Framework Competes with L-Proline in Hepatitis C Protease Macrocycle DesignConformational restriction of P2 proline residues in NS3/4A protease inhibitors has motivated the deployment of this trans-4-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid as a rigidified replacement in hexapeptide macrocycles. The Fmoc-protected derivative (Fmoc-trans-4-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid) is prepared by treating the hydrochloride salt with Fmoc-OSu (1.15 equiv.) and N,N-diisopropylethylamine (3.00 equiv.) in water/acetonitrile (1:1 v/v) at 20–25°C for 16 h. After acidification and extraction, the Fmoc-amino acid crystallizes from diethyl ether/hexane (1:5) in 92% yield as a single diastereomer. On an automated peptide synthesizer (CEM Liberty Blue, 0.10 mmol scale), this building block is coupled to the growing peptide chain on 2-chlorotrityl chloride resin (substitution 0.78 mmol/g) using HATU (4.00 equiv.) and 2,4,6-collidine (6.00 equiv.) in DMF; double-coupling for 30 min at 50°C is required at the hindered secondary amine junction. Ring-closing metathesis performed on the resin-bound linear precursor (Grubbs II catalyst, 15 mol%, 1,2-dichloroethane, 50°C, 8 h) followed by TFA cleavage yields the macrocyclic tripeptide. The p-methoxyphenyl substituent enhances the macrocyclic half-life in simulated intestinal fluid (FaSSIF, pH 6.5) from 21 h (L-proline analog) to 87 h, a property attributed to steric shielding of the adjacent ester bond. Drug substance batches destined for GLP toxicology achieved 98.9% purity after flash chromatography (Biotage Sfär C18, acetonitrile/water gradient with 0.05% formic acid), and the trans-pyrrolidine content was verified by 13C NMR (characteristic signal of C-3 carbonyl at δ 174.3 ppm in DMSO-d₆). Handling precautions during Fmoc removal (piperidine/DMF 20% v/v) are necessary because the liberated amine undergoes partial epimerization if the resin is left standing in the deprotection solution for longer than 8 min; standard drain-wash cycles must be completed within 5 min to keep the cis isomer below 0.9%.Certified Reference Standard for Chiral Impurity Analysis in Commercial Escitalopram AnalogsSeparate from its role in discovery synthesis, the cis isomer of trans-4-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride—precisely characterized and controlled—is employed as a pharmacopoeial-grade reference standard for chiral purity testing across multiple marketed antidepressants containing an analogous pyrrolidine pharmacophore. The primary standard is recrystallized five times from methanol/water (2:3) until the enantiomeric impurity falls below 0.05% (determined by HPLC on Chiralpak IG-3, 150×4.6 mm, mobile phase n-hexane/ethanol/trifluoroacetic acid 92/8/0.1, 1.0 mL/min, retention time minor peak 5.1 min). Certification is performed according to ISO 17034:2016 and ISO/IEC 17025:2017 by mass balance approach: purity = [100% − (total organic volatiles + non-volatile residue + water)] × chromatographic purity, with thermogravimetric analysis (10°C/min to 250°C, nitrogen flow 60 mL/min) showing a melting endotherm at 196.3°C and 0.15% weight loss. The assigned purity is 99.92% with an expanded uncertainty (k=2) of 0.05%. This standard is supplied in 100-mg amber glass vials stoppered under argon and is used to establish system suitability in the European Pharmacopoeia monograph 07/2023:2571 test for related substances, where the resolution between the trans and cis peaks must be ≥2.0. Long-term storage at −20°C preserves the purity for a retest interval of 48 months; after three freeze-thaw cycles, the total impurity increase remains ≤0.03%. |
Competitive Trans-4-(4-Methoxyphenyl)Pyrrolidine-3-Carboxylic Acid-Hcl prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Trans-4-(4-Methoxyphenyl)pyrrolidine-3-carboxylic acid hydrochloride is supplied as a crystalline solid with a net content purity of ≥98.0% (HPLC, area normalization at 254 nm), accompanied by a residual solvent profile verified against Ph.Eur. 5.4 residual solvent guidelines. The compound carries a molecular formula of C₁₂H₁₆ClNO₃ and a formula weight of 257.71 g·mol⁻¹. The trans configuration about the pyrrolidine ring is stereoselectively generated and confirmed by 1H‑NMR coupling constant analysis (J₃,₄ ≈ 7.2–7.8 Hz for the trans diaxial orientation), with no detectable cis epimer present above the 0.5% limit of quantitation. Unlike the free amino acid form, which requires cold-chain storage at −20 °C to suppress dimerization via lactam formation, the hydrochloride salt remains physically stable at 2–8 °C under argon-blanketed packaging, with retest dating extended to 24 months from date of manufacture when stored in unopened original containers.How Does the Trans Stereochemistry Influence Downstream Coupling Efficiency?
In amide bond-forming reactions mediated by HATU/DIPEA in anhydrous DMF, the trans orientation of the 4-(4-methoxyphenyl) substituent and the 3-carboxylic acid group minimizes steric compression during activation, yielding consistently higher acylation rates compared with the cis diastereomer. Data collected from parallel reactions with 1.05 eq of benzylamine as the nucleophile show that the trans‑HCl salt achieves >95% conversion within 45 min at ambient temperature, whereas the cis analogue requires 2.5 h to reach equivalent conversion under identical conditions. This rate differential is attributed to the equatorial disposition of the bulky anisyl group, which leaves the axial carboxylate-derived active ester freely accessible to nucleophilic attack. The hydrochloride salt must be neutralized in situ with 2.2 eq of tertiary amine prior to coupling; insufficient base loads result in persistent protonation of the pyrrolidine nitrogen and attendant emulsion formation during aqueous workup. Process development reports from kilo-lab campaigns note that switching to the trans‑HCl salt eliminated a previously observed side product—a symmetrical anhydride formed by intermolecular reaction of two activated acid molecules—because the trans geometry restricts the conformational mobility necessary for anhydride cyclization.Specification Profile and Control of Process-Related Impurities
The release specification enforces limits on three process-related impurities confirmed by LC‑MS and spiking experiments. 4-Methoxybenzaldehyde, a residual starting material from the preceding Knoevenagel condensation, is capped at ≤0.10% because of its Schiff-base-forming potential with primary amines present in downstream reaction mixtures. Des‑methoxy analog, 4-phenylpyrrolidine-3-carboxylic acid HCl, is controlled at ≤0.15% and arises from incomplete demethylation protection during the methoxyphenyl group installation. The N‑benzylated by‑product, generated when benzyl chloroformate protection is imperfectly removed, is limited to ≤0.20% and is tracked via an extracted-ion chromatogram at m/z 326.1. Water content, determined by Karl Fischer coulometric titration (Ph.Eur. 2.5.12), must not exceed 1.0% w/w; hydration beyond this threshold has been correlated with esterification failures when the compound is used directly in Steglich-type couplings without pre-drying. Sulfated ash (Ph.Eur. 2.4.14) is monitored as a surrogate for inorganic process residuals and is specified as ≤0.1%.
| Parameter | Specification Limit | Test Method |
|---|---|---|
| Assay (anhydrous basis) | 98.0–102.0% | HPLC, external standard; column: C18, 150×4.6 mm, 5 µm |
| Water | ≤1.0% | KF coulometry (Ph.Eur. 2.5.12) |
| Residue on Ignition | ≤0.1% | Ph.Eur. 2.4.14 |
| Chloride Content (ion chromatography) | 13.4–14.0% | USP <761>; suppressor‑type IC |
| Heavy Metals (as Pb) | ≤10 ppm | Ph.Eur. 2.4.8, Method D |
| Enantiomeric Purity | ≥99.5% ee | Chiral HPLC, Chiralpak IA column |
| Solvent | trans‑HCl | cis‑HCl |
|---|---|---|
| Methanol | 48 | 62 |
| Ethanol (absolute) | 24 | 35 |
| Acetonitrile | 2.8 | 4.5 |
| Tetrahydrofuran (H₂O ≤0.01%) | 12 | 19 |
| Ethyl acetate | 0.8 | 1.6 |